March 11, 2021
The total number of doses of Covaxin administered till February 9 was 3.03 lakh - PTI
The total number of doses of Covaxin administered till February 9 was 3.03 lakh - PTI×
DCGI panel seen scrapping ‘clinical trial mode’ condition for the Bharat Biotech vaccine, based on 81 per cent efficacy report
The acceptance for Covaxin, the Covid-19 vaccine developed entirely by the Hyderabad-based Bharat Biotech, appears to be rising perhaps after Prime Minister Narendra Modi took it, on March 1.
Even as an official source confirmed to
BusinessLine on Tuesday that the Health Ministry has ordered for 45 lakh doses of Covaxin for delivery by March 16, in another significant development, an independent Subject Expert Committee of the Drugs Controller General of India (DCGI) is learnt to have recommended ending the “clinical trial mode” condition for the vaccine, based on interim clinical trials results which showed 81 per cent efficacy. A final decision from the DCGI is expected on Thursday, it is learnt. Bharat Biotech has already supplied 55 lakh doses so far.